CORD-19:0329e0f2e3b8ab0eabe2afe0e5214cc88c61080e / 1693-1882 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T10","span":{"begin":0,"end":189},"obj":"Sentence"},{"id":"T8362","span":{"begin":0,"end":189},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Favipiravir has been submitted for additional indications for severe fever with thrombocytopenia syndrome (SFTS) based on clinical trials (Yasukawa, 2016) in addition to influenza in Japan."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T10","span":{"begin":0,"end":189},"obj":"Sentence"}],"text":"Favipiravir has been submitted for additional indications for severe fever with thrombocytopenia syndrome (SFTS) based on clinical trials (Yasukawa, 2016) in addition to influenza in Japan."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T21","span":{"begin":80,"end":96},"obj":"Disease"},{"id":"T22","span":{"begin":170,"end":179},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Favipiravir has been submitted for additional indications for severe fever with thrombocytopenia syndrome (SFTS) based on clinical trials (Yasukawa, 2016) in addition to influenza in Japan."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1","span":{"begin":69,"end":74},"obj":"Phenotype"},{"id":"T2","span":{"begin":80,"end":96},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0001873"}],"text":"Favipiravir has been submitted for additional indications for severe fever with thrombocytopenia syndrome (SFTS) based on clinical trials (Yasukawa, 2016) in addition to influenza in Japan."}